Teva Pharmaceutical Industries (TEVA) Return on Sales (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Return on Sales for 18 consecutive years, with 0.0% the latest figure, recorded in Q1 2026.

• Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Sales slipped to 0.0% in Q1 2026 per TEVA's latest filing, from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for TEVA reached as high as 0.0% in Q1 2024 and fell as low as 0.0% in Q4 2023.
• A 5-year average of 0.0% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• The largest YoY upside for Return on Sales was 0 bps in 2022 against a maximum downside of 0 bps in 2022.
• Year by year, Return on Sales stood at 0.0% in 2022, then decreased by 17 bps to 0.0% in 2023, then surged by 76 bps to 0.0% in 2024, then surged by 205 bps to 0.0% in 2025, then declined by 7 bps to 0.0% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.